Clinical Trials
53
Trial Phases
5 Phases
Drug Approvals
16
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects
- Conditions
- Healthy Volunteers
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 78
- Registration Number
- NCT05413863
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH 9, Neuss, Germany
Efficacy and Safety of Itolizumab in COVID-19 Complications
- Conditions
- Acute Respiratory Distress SyndromeCytokine Release SyndromeCovid19
- Interventions
- Drug: Best supportive care (BSC)
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 32
- Registration Number
- NCT04475588
- Locations
- 🇮🇳
Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India
🇮🇳Seth GS Medical College and KEM Hospital, Mumbai, India
🇮🇳MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India
Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil
- Conditions
- Type 1 Diabetes Mellitus (T1DM)
- Interventions
- Drug: Tregopil
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 55
- Registration Number
- NCT04141423
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany
Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N
- Conditions
- Healthy Volunteer
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 90
- Registration Number
- NCT04022304
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30
- Conditions
- Healthy Volunteer
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 78
- Registration Number
- NCT04022291
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany
🇩🇪Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss, Neuss, Germany
- Prev
- 1
- 2
- Next
News
FDA Approves Kirsty as First Interchangeable Rapid-Acting Insulin Aspart Biosimilar
The FDA has approved Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar to NovoLog, expanding treatment options for diabetes patients.
Biocon Receives Indian Regulatory Approval for Generic Liraglutide, Expanding GLP-1 Diabetes Treatment Access
Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.
Biocon Pharma Secures FDA Approval for Norepinephrine Bitartrate Injection for Acute Hypotension
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received FDA approval for Norepinephrine Bitartrate Injection USP, used to raise blood pressure in adults with acute hypotension.
Itolizumab Shows Promising Results in Phase 2 Ulcerative Colitis Trial, Matching Adalimumab Efficacy
Itolizumab demonstrated a 23.3% clinical remission rate in moderate to severe ulcerative colitis patients after 12 weeks, comparable to adalimumab's 20.0% and superior to placebo's 10.0%.